Avicanna Inc (AVCN) Fair Value & Analysis
Healthcare · CA · Market cap C$15.7M
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 4 days ago
Fair value updated Jun 26, 2026 — revised from C$0.1000 to C$0.0200 (−80.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range C$0.1100 – C$0.2950 · fair‑value band C$0.0100 – C$0.0200 · the C$0.1250 price screens above the C$0.0200 fair value. As of Jun 26, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Avicanna Inc (AVCN) currently trades at C$0.1250, while our model-based Fair Value estimate is C$0.0200 — implying the stock looks roughly 84.0% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Avicanna Inc generated revenue of C$25.8M at a net margin of -12.1%. Revenue grew 5.6% year over year. It earns a return on equity of -26.5%. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, as well as Trunerox, an indication-specific drug treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta bra…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Avicanna Inc reported revenue of C$25.5M in FY2025 versus C$3.3M in FY2021, a compound +67.1%/yr. Reported net income was −C$2.8M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Avicanna Inc (AVCN) undervalued?
What is the fair value of AVCN?
What is the quality score of AVCN?
What is the revenue of Avicanna Inc (AVCN)?
What is the net profit margin of AVCN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.